Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

ABSTRACT Background Gemcitabine plus cisplatin (GC) has been the global standard for advanced biliary tract cancer (BTC). The triplet regimen gemcitabine–cisplatin–S‐1 (GCS) demonstrated superiority in the MITSUBA trial, but its real‐world effectiveness remains unclear. We compared survival outcomes...

Полное описание

Библиографические подробности

Главные авторы:	Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, Toru Ishikawa, Takanori Morikawa, Jun Hanaoka, Haruki Mori, Hidenori Toyoda, Tsuyoshi Sanuki, Misaki Yokoi, Hiroyuki Shibata, Koji Fukuda, Kazuhito Kawata, Koji Amaya, Takashi Ito, Masaaki Hidaka, Atsushi Naganuma, Keishi Sugimachi, Satoshi Toshiyama, Makoto Yamasaki, Masaki Kaibori
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2026-07-01
Серии:	Annals of Gastroenterological Surgery
Предметы:	biliary tract neoplasms cholangiocarcinoma cisplatin gemcitabine Tegafur Gimeracil Oteracil potassium (S‐1)
Online-ссылка:	https://doi.org/10.1002/ags3.70202
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!